Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 9 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Survodutide improves HbA1c and bodyweight in type 2 diabetes
Última actualización 5 de julio de 2026
Key finding
HbA 1c decreased from baseline (mean ± SD 64.7 ± 9.2 mmol/mol) after 16 weeks’ treatment.
This Phase II study evaluated the effects of Survodutide on HbA1c levels and bodyweight in adults with Type 2 Diabetes, finding significant reductions in both outcomes compared to baseline.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This Phase II study evaluated the effects of Survodutide on HbA1c levels and bodyweight in adults with Type 2 Diabetes, finding significant reductions in both outcomes compared to baseline.
Clinical relevance
These findings are clinically significant as they suggest that Survodutide could be an effective treatment option for managing Type 2 Diabetes, potentially leading to better glycemic control and weight management for patients. Effective management of these parameters is crucial in reducing the risk of diabetes-related complications.
Keep in mind
The study did not include long-term follow-up data. Sample size and demographic diversity were not specified. Effectiveness of Survodutide compared to other treatments was not fully explored.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Matthias B, Julio R, Josef H, Raymond M, Anita MH. Survodutide Reduces HbA1c Levels and Bodyweight in Adults with Type 2 Diabetes: A Phase II Study. Diabetologia. 2023;67(3):470-482. doi:10.1007/s00125-023-06053-9
Efectos Principales
HbA1c decreased by -9.92 mmol/mol (p=0.001) after treatment with Survodutide.
Bodyweight decreased by up to -8.7% with Survodutide.
No significant change in HbA1c levels was observed in the placebo group.
Bodyweight change with Semaglutide was not significantly different from placebo.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Survodutide and Body weight, HbA1c.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
3
Evidence pairs
3
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
3
Evidence pairs
546
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 3 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Tema de evidencia
Weight Loss
Guardar evidencia
Tema de evidencia
HbA1c Reduction
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Survodutide reduced HbA1c levels by -9.92 mmol/mol.
- Bodyweight decreased by up to -8.7% with Survodutide.
- Placebo showed no significant changes in HbA1c levels.
A quién se aplica
- Adults diagnosed with Type 2 Diabetes.
- Individuals seeking new treatment options for diabetes management.
Tener en Cuenta
- Results are based on a 16-week treatment period.
- Findings may not be generalizable to all populations.
- Further studies are needed to assess long-term effects and safety.
Entre Líneas
- The study did not include long-term follow-up data.
- Sample size and demographic diversity were not specified.
- Effectiveness of Survodutide compared to other treatments was not fully explored.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 9 estudios
View evidenceMedications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Estudios de apoyo: Basado en 11 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
9 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
9 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
9 results
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Semaglutide
Intervention: Semaglutide
9 results
All studies measuring Body weight
Outcome: Body weight
9 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 86.7 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Survodutide improve HbA1c?
Emerging Evidence
Survodutide appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Survodutide affect body weight?
Emerging Evidence
Current evidence does not show a clear benefit of Survodutide for Body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.